Evidence map›Paper›PMID 34208043›Full record

ArticleJournal of personalized medicine2021

A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets.

Ester Blanco, Maria Ibañez-Vea, Carlos Hernandez, Lylia Drici, Xabier Martínez de Morentin, Maria Gato, Karina Ausin, Ana Bocanegra, Miren Zuazo, Luisa Chocarro and 14 more

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. CAR-T Cells for the Treatment of Lung Cancer.Life (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ester BlancoOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.ORCID 0000-0002-2980-7137
Maria Ibañez-VeaOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Carlos HernandezOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.ORCID 0000-0001-8536-429X
Lylia DriciThe Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
Xabier Martínez de MorentinBioinformatics Group, Navarrabiomed Biomedical Research Center, Institute of Health Carlos III (ISCIII), Navarra Institute for Health Research (IdiSNA), Irunlarrea 3, 31008 Pamplona, Spain.
Maria GatoOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Karina AusinProteored-ISCIII, Proteomics Platform, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.ORCID 0000-0003-4914-9466
Ana BocanegraOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.ORCID 0000-0002-3508-0595
Miren ZuazoOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Luisa ChocarroOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Hugo ArasanzOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.ORCID 0000-0001-6838-6702
Gonzalo Fernandez-HinojalOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Joaquin Fernandez-IrigoyenProteored-ISCIII, Proteomics Platform, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.
Cristian SmerdouDivision of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain.
Maider GarnicaOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Miriam EchaideOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Leticia FernandezOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Pilar MorenteOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Pablo Ramos-CastellanosOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Diana LlopizCentro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, 31008 Pamplona, Spain.
Enrique SantamariaProteored-ISCIII, Proteomics Platform, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdISNA, Irunlarrea 3, 31008 Pamplona, Spain.ORCID 0000-0001-8046-8102
Martin R LarsenDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark.
David EscorsOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.
Grazyna KochanOncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain.

Funding

Departamento de Salud, Gobierno de Navarra BMED 050-2019Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra AGATA, Ref 0011-1411-2020-000013Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra DESCARTHES, 0011-1411-2019-000058Dirección General de Industria, Energia y Proyectos Estrategicos S3, Gobierno de Navarra LINTERNA, Ref. 0011-1411-2020-000033Fundación Científica Asociación Española Contra el Cáncer PROYE16001ESCOHorizon 2020 Framework Programme ISOLDA; ID: 848166Instituto de Salud Carlos III COV20/00000Instituto de Salud Carlos III FIS PI17/02119Instituto de Salud Carlos III PI20/00010Instituto de Salud Carlos III TRANSPOCART ICI19/00069
6 · The paper itself

Abstract

Monocytic and granulocytic myeloid-derived suppressor cells together with tumor-infiltrating macrophages constitute the main tumor-infiltrating immunosuppressive myeloid populations. Due to the phenotypic resemblance to conventional myeloid cells, their identification and purification from within the tumors is technically difficult and makes their study a challenge. We differentiated myeloid cells modeling the three main tumor-infiltrating types together with uncommitted macrophages, using ex vivo differentiation methods resembling the tumor microenvironment. The phenotype and proteome of these cells was compared to identify linage-dependent relationships and cancer-specific interactome expression modules. The relationships between monocytic MDSCs and TAMs, monocytic MDSCs and granulocytic MDSCs, and hierarchical relationships of expression networks and transcription factors due to lineage and cancer polarization were mapped. Highly purified immunosuppressive myeloid cell populations that model tumor-infiltrating counterparts were systematically analyzed by quantitative proteomics. Full functional interactome maps have been generated to characterize at high resolution the relationships between the three main myeloid tumor-infiltrating cell types. Our data highlights the biological processes related to each cell type, and uncover novel shared and differential molecular targets. Moreover, the high numbers and fidelity of ex vivo-generated subsets to their natural tumor-shaped counterparts enable their use for validation of new treatments in high-throughput experiments.

Indexed as

cancermyeloid-derived suppressor cellstumor-infiltrating macrophages

Identifiers

PMID34208043
PMCPMC8230595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.